# OnCo record replimune (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/replimune/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "replimune" ;
  schema:name "Replimune"@en ;
  schema:description "Oncolytic virus company whose RP1 (Tudriqev) was approved in August 2026 after an initial FDA rejection."@en ;
  schema:url <https://onco.cc/companies/replimune/>, <https://www.replimune.com> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://www.replimune.com> ;
  schema:addressCountry "US" ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:drugs <https://onco.cc/drugs/vusolimogene-oderparepvec/> ;
  onco:trials <https://onco.cc/trials/nct06581406/>, <https://onco.cc/trials/nct04050436/>, <https://onco.cc/trials/nct03767348/>, <https://onco.cc/trials/nct05733598/>, <https://onco.cc/trials/nct04349436/> .